SCHEDULE: Vanguard Group Reports 0% Stake in United Therapeutics

The Vanguard Group reports 0% beneficial ownership in United Therapeutics Corp following an internal realignment.

Summary

• The Vanguard Group, Inc. (Vanguard) has reported 0% beneficial ownership of United Therapeutics Corp's Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• In accordance with SEC Release No. 34-39538, certain subsidiaries or business divisions of Vanguard will now report beneficial ownership separately (on a disaggregated basis).
• Vanguard no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
• The filing is an Amendment No. 13 to Schedule 13G for United Therapeutics Corp.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, primarily an administrative change in how Vanguard reports its holdings rather than a strategic investment decision regarding United Therapeutics. It does not reflect a change in the fundamental outlook for United Therapeutics.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding United Therapeutics Corp's future performance or The Vanguard Group's investment strategies beyond the reporting change.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that internal realignments and subsequent changes in reporting structure are common for large, diversified asset management firms like The Vanguard Group. This typically reflects an operational or compliance adjustment rather than a change in investment thesis or a complete divestment from the underlying company by the broader organization.

Stakeholder Impact

• Shareholders of United Therapeutics Corp should be aware that The Vanguard Group, Inc. itself no longer reports beneficial ownership, but this does not necessarily mean a reduction in total institutional ownership by Vanguard-affiliated entities, as subsidiaries will now report separately.

Key Dates

Keywords

Vanguard Group, United Therapeutics, Schedule 13G, beneficial ownership, institutional ownership, SEC filing, investment management, corporate realignment